Squamous cell carcinoma of the lung chemotherapy: Difference between revisions

Jump to navigation Jump to search
Maria Villarreal (talk | contribs)
Maria Villarreal (talk | contribs)
No edit summary
Line 5: Line 5:
==Overview==
==Overview==


Chemotherapy is indicated for squamous cell carcinoma of the lung stage (IB, II, and III) as adjuvant therapy. The predominant treatment of choice for squamous cell carcinoma of the lung is surgical resection. Chemotherapy and chemoradiation may be required upon histological subtype of squamous cell carcinoma of the lung, location, size, and lymph node involvement. Commonly used chemotherapeutic agents, include: erlotinib, paclitaxel, docetaxel, carboplatin, etoposide or vinorelbine.<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref><ref name="wikip"> Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330</ref>
Chemotherapy may be required upon histological subtype of squamous cell carcinoma of the lung, molecular testing (presence of genetic mutations), and staging. In most cases, the predominant treatment of choice for squamous cell carcinoma of the lung is neoadjuvant chemotherapy or adjuvant chemotherapy, followed or preceded by surgical resection. Commonly used chemotherapeutic agents, include: cisplatin, erlotinib, paclitaxel, docetaxel, carboplatin, etoposide or vinorelbine.<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref><ref name="wikip"> Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330</ref>


==Chemotherapy==
==Chemotherapy==
*Initial chemotherapy for patients with squamous cell carcinoma of the lung will depend on molecular testing (presence of genetic mutations)  
 
*Combination chemotherapy regimens using a platinum-based chemotherapy is the treatment of choice for the management of patients with squamous cell carcinoma of the lung  
*Initial chemotherapy for patients with squamous cell carcinoma of the lung will depend on molecular testing, the presence of particular genetic mutations, and staging.
*Chemotherapy for patients with squamous cell carcinoma of the lung, is divided into 2 main types: specific-inhibitor therapy (usually indicated with the presence of a genetic mutation) and platinum-based chemotherapy ( usually indicated with the absence of a genetic mutation)
*Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with squamous cell carcinoma of the lung  
*Erlotinib is the first-line treatment for patients with squamous cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations.
*Erlotinib is the first-line treatment for patients with squamous cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations.
*Chemotherapy treatments for squamous cell carcinoma of the lung, include:<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref>
*Chemotherapy treatments for squamous cell carcinoma of the lung, include:<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref>
Line 25: Line 27:
:*Docetaxel  
:*Docetaxel  
:*Pemetrexed
:*Pemetrexed
*Chemotherapy is indicated as adjuvant for stage IB, II, and III squamous cell carcinoma of the lung. The predominant treatment of choice for squamous cell carcinoma of the lung is surgical resection
*Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung  
*Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung  
*Platinum-based chemotherapy  consists of four to six cycles
*Platinum-based chemotherapy  consists of four to six cycles
* To see more detailed information about the chemotherapeutic regimens in non-small cell lung cancer click [[Non small cell lung cancer chemotherapy#Chemotherapeutic Regimens|here]]
*Cisplatin is the preferred platinum based agent of choice when the therapy is used with curative intent
* To see more information about mangnagment approach for  non-small cell lung cancer click [[Non small cell lung cancer management#Management Approach|here]]
* To see more information about the chemotherapeutic regimens in non-small cell lung cancer click [[Non small cell lung cancer chemotherapy#Chemotherapeutic Regimens|here]]


==Complications==
==Complications==

Revision as of 19:33, 7 March 2016

Squamous Cell Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Squamous Cell Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Squamous cell carcinoma of the lung chemotherapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Squamous cell carcinoma of the lung chemotherapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Squamous cell carcinoma of the lung chemotherapy

CDC on Squamous cell carcinoma of the lung chemotherapy

Squamous cell carcinoma of the lung chemotherapy in the news

Blogs on Squamous cell carcinoma of the lung chemotherapy

Directions to Hospitals Treating Squamous cell carcinoma of the lung

Risk calculators and risk factors for Squamous cell carcinoma of the lung chemotherapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2] Maria Fernanda Villarreal, M.D. [3]

Overview

Chemotherapy may be required upon histological subtype of squamous cell carcinoma of the lung, molecular testing (presence of genetic mutations), and staging. In most cases, the predominant treatment of choice for squamous cell carcinoma of the lung is neoadjuvant chemotherapy or adjuvant chemotherapy, followed or preceded by surgical resection. Commonly used chemotherapeutic agents, include: cisplatin, erlotinib, paclitaxel, docetaxel, carboplatin, etoposide or vinorelbine.[1][2]

Chemotherapy

  • Initial chemotherapy for patients with squamous cell carcinoma of the lung will depend on molecular testing, the presence of particular genetic mutations, and staging.
  • Chemotherapy for patients with squamous cell carcinoma of the lung, is divided into 2 main types: specific-inhibitor therapy (usually indicated with the presence of a genetic mutation) and platinum-based chemotherapy ( usually indicated with the absence of a genetic mutation)
  • Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with squamous cell carcinoma of the lung
  • Erlotinib is the first-line treatment for patients with squamous cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations.
  • Chemotherapy treatments for squamous cell carcinoma of the lung, include:[1]
  • Paclitaxel
  • Cisplatin
  • Erlotinib
  • Afatinib
  • Gefitinib
  • Bevacizumab
  • Crizotinib
  • Vinorelbine
  • Gemcitabine
  • Carboplatin
  • Etoposide
  • Docetaxel
  • Pemetrexed
  • Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung
  • Platinum-based chemotherapy consists of four to six cycles
  • Cisplatin is the preferred platinum based agent of choice when the therapy is used with curative intent
  • To see more information about mangnagment approach for non-small cell lung cancer click here
  • To see more information about the chemotherapeutic regimens in non-small cell lung cancer click here

Complications

  • Medical therapy complications for squamous cell carcinoma of the lung will depend on the chemotherapeutic agent.
  • Common chemotherapy complications, include:[1]
  • Platinum-based chemotherapy, the main dose-limiting side effect of cancer treatment with platinum compounds, include:
  • Other chemotherapeutic agent complications, include:
  • Side effects symptoms of chemotherapeutic agents, include:

References

  1. 1.0 1.1 1.2 Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899
  2. Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330


Template:WikiDoc Sources